5PSQ-040 Security profile of ibrutinib as monotherapy in patients with chronic lymphocytic leukaemia: experience in a tertiary hospital

Background and importanceIbrutinib is a tyrosine kinase inhibitor indicated for the treatment of chronic lymphocytic leukaemia (CLL) among other pathologies.Aim and objectivesTo assess the frequency and severity of adverse events (AEs) in CLL patients treated with ibrutinib.Material and methodsThis...

Full description

Bibliographic Details

Published in:	European journal of hospital pharmacy. Science and practice Vol. 27; no. Suppl 1; p. A168
Main Authors:	Fernandez Cuerva, C, Ortega De La Cruz, C, Ortiz, M, Muñoz Castillo, MI
Format:	Journal Article
Language:	English
Published:	London BMJ Publishing Group LTD 01-03-2020
Subjects:	Computerized physician order entry Cytogenetics Leukemia Neutropenia Targeted cancer therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!